Methods of producing anamorelin hydrochloride having controlled chloride content

US9956261B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9956261-B2
Application numberUS-201615135107-A
CountryUS
Kind codeB2
Filing dateApr 21, 2016
Priority dateApr 20, 2012
Publication dateMay 1, 2018
Grant dateMay 1, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.

First claim

Opening claim text (preview).

The invention claimed is: 1. Anamorelin monohydrochloride comprising less than 3% total impurities selected from by-products, contaminants, and degradation products. 2. The anamorelin monohydrochloride of claim 1 , comprising less than 2% total impurities selected from by-products, contaminants, and degradation products. 3. The anamorelin monohydrochloride of claim 1 , comprising less than 1% total impurities selected from by-products, contaminants, and degradation products. 4. The anamorelin monohydrochloride of claim 1 , comprising less than 5% water. 5. The anamorelin monohydrochloride of claim 1 , comprising less than 3% water. 6. The anamorelin monohydrochloride of claim 1 , comprising less than 2% water. 7. The anamorelin monohydrochloride of claim 1 in an isolated state. 8. The anamorelin monohydrochloride of claim 1 in combination with one or more pharmaceutically acceptable excipients. 9. The anamorelin monohydrochloride of claim 1 in combination with one or more pharmaceutically acceptable excipients in the form a tablet or capsule or pellets or granules or powders. 10. The anamorelin monohydrochloride of claim 1 having a solubility in water greater than 100 mg/mL. 11. The anamorelin monohydrochloride of claim 1 having a solubility in water greater than 333 mg/mL. 12. The anamorelin monohydrochloride of claim 1 having a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 13. The anamorelin monohydrochloride of claim 1 having a stability defined by a percentage increase in impurities of no more than 48% when stored at 25° C. and a relative humidity of 60% for two years. 14. The anamorelin monohydrochloride of claim 1 having a chloride content of from 5.6 to 6.3%. 15. The anamorelin monohydrochloride of claim 1 having a residual solvent concentration less than 5000 ppm, wherein the residual solvent concentration excludes water. 16. The anamorelin monohydrochloride of claim 1 , wherein the anamorelin monohydrochloride has a solubility in water greater than 333 mg/mL, and a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 17. The anamorelin monohydrochloride of claim 1 having a chloride content of from 5.6 to 6.2% and a residual solvent concentration excluding water less than 5000 ppm, a solubility in water greater than 333 mg/mL, and a stability defined by a percentage increase in impurities of no more than 114% when stored at 25° C. and a relative humidity of 60% for two years. 18. Anamorelin monohydrochloride comprising: a) less than 3% total impurities selected from by-products, contaminants, and degradation products; b) a residual solvent concentration excluding water of less than 5000 ppm; and c) a chloride content of from 5.6 to 6.2%.

Assignees

Inventors

Classifications

  • Anorexiants; Antiobesity agents · CPC title

  • the side chain containing 2 to 4 carbon atoms · CPC title

  • A61K38/05Primary

    Dipeptides · CPC title

  • linked by a chain containing hetero atoms as chain links · CPC title

  • C07D401/06Primary

    linked by a carbon chain containing only aliphatic carbon atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9956261B2 cover?
The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
Who is the assignee on this patent?
Helsinn Healthcare Sa, Ono Pharmaceutical Co
What technology area does this patent fall under?
Primary CPC classification A61K38/05. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).